Amgen olpasiran may fill critical treatment gap in lowering Lp(a): GlobalData
This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)
This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)
Patients Treated with ARIKAYCE plus macrolide-based background regimen had meaningfully larger improvements in QOL-B respiratory score
This indigenously developed enhanced care technology is designed to continuously monitor and detect early signs of deterioration in a patient's condition
The cognitively operated system is a mother patent invention, first launched in India
Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products
This approval has come from the company's finished dosage form manufacturing facility
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Health Assurance is a unique healthcare model that combines health insurance with preventive healthcare with a focus on keeping people healthy while providing sick care for them when needed
Robots make it to the healthcare conference panel, reflecting the future potential of technology
Subscribe To Our Newsletter & Stay Updated